echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 5-year compound growth rate: 184%, weight-bearing hypoglycemic drug: dongyangguang medicine, first imitated by Yangtze River

    5-year compound growth rate: 184%, weight-bearing hypoglycemic drug: dongyangguang medicine, first imitated by Yangtze River

    • Last Update: 2019-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to data from minenet, the listing application of gligliptin tablets submitted by Shanghai haini Pharmaceutical Co., Ltd of Yangzi River according to four generic drugs was accepted by CDE on November 27 At present, only the products of the original manufacturer, bringer Ingelheim, are sold on the market in the domestic market In 2018, the sales volume at the terminals of public medical institutions in China was 120 million yuan, an increase of 144.56% year on year As a dipeptidyl peptidase 4 (DPP-4) inhibitor, liggliptin can be used in combination with metformin hydrochloride to improve blood glucose control on the basis of diet and exercise, and it can be used for blood glucose control in adult type 2 diabetic patients At present, 5 DPP-4 inhibitors have been approved for listing in the domestic market, and the first ones have been approved Although the market share of DPP-4 inhibitors in diabetes drugs is relatively small, the market share of DPP-4 inhibitors represented by cigliptin is increasing in recent years With cigliptin, saggliptin, viggliptin, liggliptin and agliptin successively entering the national medical insurance catalog, more and more generic drugs have been approved In the future, DPP-4 inhibitors will be further increased in large amount and achieve rapid growth as a whole Liggliptin tablet was first developed by bringer Ingelheim, and was approved to be listed in the United States in 2011, and approved to enter the domestic market in 2013 According to data from minet.com, sales of liggliptin tablets rose all the way after they were approved to enter the domestic market In 2018, the sales volume of terminals in public medical institutions in China exceeded 100 million yuan, with a year-on-year growth of 144.56%, and the compound growth rate reached 184.41% in five years The sales prospect is bright.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.